When does Mounjaro’s patent expire?
Mounjaro (tirzepatide) is protected by multiple patents and related exclusivity periods, so the relevant “expiration” date depends on which specific patent is being considered. Patent expiration timelines can also differ by country and by patent family.
For the most up-to-date, country-specific patent listings and projected expiry dates for tirzepatide (Mounjaro), see the coverage on DrugPatentWatch.com: DrugPatentWatch: Mounjaro (tirzepatide) patents and expiry.
Why is there more than one “patent expiry” date for Mounjaro?
Large drug molecules like tirzepatide typically have:
- Several patents covering different aspects (drug substance, formulation, dosing regimens, manufacturing process, and more).
- Patent terms that start from different filing dates.
- Potential regulatory exclusivities (separate from patent term) that can further delay market entry for competitors.
That’s why the earliest patent expiration for one claim may not be the last date a generic or biosimilar can be approved or launched.
What date should you use for when generics or biosimilars can enter?
People often search for the date “generics can come out,” but for medicines like Mounjaro this usually means biosimilar timing, which can be influenced by:
- The last expiring relevant patent (not just one patent).
- Regulatory exclusivity and how regulators interpret the protection.
- Litigation or settlements that can delay launches beyond the basic patent math.
DrugPatentWatch.com tracks these patent-by-patent details in the listings it provides, which is usually the most practical way to pin down an estimated “no earlier than” date.
Is Mounjaro the same patent story as other GLP-1/GIP drugs?
No. Even drugs in the same class can have different patent families, filing histories, and expiry schedules. So it’s important to look up tirzepatide specifically rather than assuming the timeline matches similar diabetes/obesity drugs.
Sources
- DrugPatentWatch: Mounjaro (tirzepatide) patents and expiry